MCK earnings call: key takeaways

• McKesson reported second quarter fiscal 2027 adjusted earnings per diluted share of $11.68, beating the $10.69 consensus estimate (18:07)
• The company raised its fiscal 2027 adjusted EPS guidance to $45.60 to $46.40 from $44.20 to $45.00 (3:55)

Results vs expectations

What changed since last quarter

• The company raised its fiscal 2027 adjusted EPS guidance to $45.60 to $46.40 from $44.20 to $45.00. (3:55)
• McKesson completed the acquisition of Precision Medicine Group for $2.25 billion, which is expected to be accretive to EPS. (14:47)
• The company announced a strategic investment in Option Care Health, a 49% minority interest, aligning with its strategy to expand access to innovative therapies. (14:47)

What analysts pressed on

• Concerns about the impact of 340B policy changes on volume and revenue. (45:20)
• Questions about the sustainability of North American pharmaceutical growth beyond the current quarter. (42:21)
• Uncertainty around the integration of new acquisitions and their impact on margins. (35:14)

In their words

• We are raising our fiscal 2027 adjusted earnings per diluted share guidance to $45.60 to $46.40 from the previous range of $44.20 to $45.00. Brian Tyler (3:55)
• Our results continue to demonstrate the benefits of our strategic focus, differentiated capabilities and disciplined capital deployment. Brian Tyler (3:55)